The case for an HIV cure and how to get there
M Dybul, T Attoye, S Baptiste, P Cherutich, F Dabis… - The Lancet …, 2021 - thelancet.com
In light of the increasing global burden of new HIV infections, growing financial
requirements, and shifting funding landscape, the global health community must accelerate …
requirements, and shifting funding landscape, the global health community must accelerate …
Defensins: defenders of human reproductive health
YJ Zhai, Y Feng, X Ma, F Ma - Human reproduction update, 2023 - academic.oup.com
BACKGROUND Reproductive tract infection is an important factor leading to male and
female infertility. Among female infertility factors, microbial and viral infections are the main …
female infertility. Among female infertility factors, microbial and viral infections are the main …
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature …
Abstract Background To inform World Health Organization (WHO) global guidelines, we
updated and expanded the evidence base to assess the comparative efficacy, tolerability …
updated and expanded the evidence base to assess the comparative efficacy, tolerability …
Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine
Y van Heuvel, S Schatz, JF Rosengarten, J Stitz - Toxins, 2022 - mdpi.com
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …
host cell factors to enable virus replication. The viral genomic RNA of the human …
[HTML][HTML] Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections
S Najafi, SC Tan, S Aghamiri, P Raee… - Biomedicine & …, 2022 - Elsevier
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus
Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel …
Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel …
Challenges of HIV diagnosis and management in the context of pre‐exposure prophylaxis (PrEP), post‐exposure prophylaxis (PEP), test and start and acute HIV …
T Elliott, EJ Sanders, M Doherty… - African Journal of …, 2019 - journals.lww.com
Introduction: Knowledge of HIV status relies on accurate HIV testing, and is the first step
towards access to HIV treatment and prevention programmes. Globally, HIV-status …
towards access to HIV treatment and prevention programmes. Globally, HIV-status …
Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance
Highlights•During ART, HIV persists latently in several cell types and tissues.•Proliferation of
latently infected cells is likely responsible for residual viremia.•DRMs do not appear during …
latently infected cells is likely responsible for residual viremia.•DRMs do not appear during …
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study
AKA Afrane, BQ Goka, L Renner, AE Yawson… - BMC infectious …, 2021 - Springer
Background Children living with human immunodeficiency virus (HIV) infection require
lifelong effective antiretroviral therapy (ART). The goal of ART in HIV-infected persons is …
lifelong effective antiretroviral therapy (ART). The goal of ART in HIV-infected persons is …
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study
Background Implementation of ultrasensitive HIV drug resistance tests for routine clinical
use is hampered by uncertainty about the clinical relevance of drug-resistant minority …
use is hampered by uncertainty about the clinical relevance of drug-resistant minority …
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
Background Paediatric dolutegravir doses approved by stringent regulatory authorities
(SRAs) for children weighing 20 kg to less than 40 kg until recently required 25 mg and 10 …
(SRAs) for children weighing 20 kg to less than 40 kg until recently required 25 mg and 10 …